Product Code: RP-ID-10151866 |
Published Date: 21 Oct 2022 |
Region: NA |
Category: Healthcare & Pharmaceuticals |
Report ID: 10151866
Market Overview:
Global Gonorrhea Testing Services Industry Market Research 2022-2030
"Due to the increase in the global prevalence of gonorrhea and the unmet demand for faster diagnostic tools, the global gonorrhea diagnostics market is expected to witness significant growth during the forecast period. According to the US Centers for Disease Control and Prevention (CDC), the prevalence of gonorrhea in recent years is about 106 parts per million per year. According to official data provided by the CDC, there were 333,004 cases of gonorrhea in the United States in 2013.
The CDC estimates that more than 820,000 people in the United States are infected with Neisseria gonorrhoeae each year, but less than half are reported. In the UK, approximately 28,000 cases are reported each year. Lack of knowledge of the disease and uncertain symptoms of the disease are factors that are expected to lead to an increase in the prevalence of the disease.
The frequent introduction of technologically advanced tools for detecting pathogenic bacteria and studying lesions is a factor in the continued growth of the market during the forecast period. In addition, due to the increasing use of illegal and over-the-counter antibiotics, such as ceftriaxone, doxycycline and azithromycin, which are used to treat diseases, gonococci have developed resistance. A recent WHO report pointed out that third-line cephalosporins failed to treat gonorrhea, especially in Japan, Australia, and Hong Kong.
According to the type of diagnostic test, the gonorrhea diagnostic market is segmented into flow cytometry, imaging, gel droplets, artificial intelligence, chromatography, differential light scattering (DLS), liposomes, monoclonal antibodies, and diagnostic test molecules. Because of the advantages associated with it, such as ease of execution, high accuracy, and performance cost, molecular diagnostics is the most popular and widely used diagnostic test.
Monoclonal antibody technology is widely used to distinguish gonorrhea from other diseases with similar symptoms. Flow cytometry is becoming more and more popular as an excellent tool for rapid diagnosis, especially among women, despite the fact that 80% of infected women do not show symptoms of the disease.
Modern technologies such as artificial intelligence and diagnostic imaging are in the testing phase and are expected to dominate the market in the future. New faster and more accurate infection detection technologies are expected to replace traditional diagnostic methods and change the market structure of the gonorrhea diagnostic market in the future.
From a geographical point of view, the gonorrhoea diagnostic market is segmented into North America, Europe, Asia Pacific, Latin America and MEA. Due to the advanced healthcare infrastructure and favorable government policies related to the diagnosis and treatment of sexually transmitted diseases, North America currently holds the largest market share.
High awareness of the disease and favorable reimbursement policies are factors that are expected to drive the market during the forecast period. Due to the prevalence of diseases in the region and the unmet market demand for effective diagnosis and treatment, it is expected that the market in the Asia Pacific and Middle East will grow faster. Increasing awareness of sexually transmitted diseases and available treatments should help new diagnostic tools for gonorrhea rather than traditional detection methods. The fast-changing lifestyle and the participation of multiple sexual partners are factors driving the market into the future.
Although the weak health care structure and low disposable income may hinder the market in many countries in the region, the market growth rate is expected to tend to trend due to the increase in the number of hospitals, commercial laboratories and new diagnostic technologies, faster speeds and lower costs stable. Program.
The main players in the market are :
Abott Laboratories, F. Hoffmann-La Roche AG, Tosoh Corporation, Siemens AG, bioMérieux, PerkinElmer, Inc. and Ortho Clinical Diagnostics. Meridian Bioscience recently passed the FDA and developed a new HSV I and II molecular amplification test illuminator in July 2015. Many other companies, such as Cigna, have been developing faster and more innovative diagnostic technologies. Faster and more accurate factors are expected to cause clinicians to frequently update diagnostic tools and use the latest technology.
This is expected to help new entrants dominate the market. Due to the development of technology and the increase in the number of global service points, the range of new entrants is expected to be huge."
Related Reports
Proof of Quality & Reliability
